Document is current
Any future updates will be listed below
-
Authors
Zapata, Luis https://orcid.org/0000-0002-1386-2019
Caravagna, Giulio https://orcid.org/0000-0003-4240-3265
Williams, Marc J. https://orcid.org/0000-0001-5524-4174
Lakatos, Eszter https://orcid.org/0000-0002-7221-6850
AbdulJabbar, Khalid
Werner, Benjamin https://orcid.org/0000-0002-6857-8699
Chowell, Diego
James, Chela
Gourmet, Lucie
Milite, Salvatore
Acar, Ahmet
Riaz, Nadeem https://orcid.org/0000-0001-9873-5862
Chan, Timothy A. https://orcid.org/0000-0002-9265-0283
Graham, Trevor A. https://orcid.org/0000-0001-9582-1597
Sottoriva, Andrea https://orcid.org/0000-0001-6709-9533
- License Information
-
More Information
Article History
Received: 27 October 2021
Accepted: 25 January 2023
First Online: 9 March 2023
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. T.A.C. and D.C. hold ownership of intellectual property on using tumor mutational burden to predict immunotherapy response, with a pending patent, which has been licensed to PGDx. The other authors declare no competing interests.
